首页> 美国卫生研究院文献>Acta Pharmaceutica Sinica. B >Functional nano-vector boost anti-atherosclerosis efficacy of berberine in
【2h】

Functional nano-vector boost anti-atherosclerosis efficacy of berberine in

机译:功能纳米载体提高小檗碱的抗动脉粥样硬化效果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Atherosclerosis (AS) is the leading cause of heart attacks, stroke, and peripheral vascular disease. Berberine (BBR), a botanical medicine, has diversified anti-atherosclerotic effects but with poor absorption. The aim of this study was to develop an effective BBR-entrapped nano-system for treating AS in high-fat diet (HFD)-fed Apoe(−/−) mice, and also explore the possible underlying mechanisms involved. Three d-α-tocopherol polyethylene glycol (PEG) succinate (TPGS) analogues with different PEG chain lengths were synthesized to formulate BBR-entrapped micelles. HFD-fed Apoe(−/−) mice were administered with optimized formula (BBR, 100 mg/kg/day) orally for 5 months. The artery plaque onset and related metabolic disorders were evaluated, and the underlying mechanisms were studied. Our data showed that, BT1500M increased BBR deposition in liver and adipose by 107.6% and 172.3%, respectively. In the Apoe(−/−) mice, BT1500M ameliorated HFD-induced hyperlipidemia and lipid accumulation in liver and adipose. BT1500M also suppressed HFD-induced chronic inflammation as evidenced by the reduced liver and adipose levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β); and decreased plasma level of TNF-α, IL-6, IL-1β, interferon-γ (IFN-γ), monocyte chemotactic protein (MCP), and macrophage inflammatory factor (MIP). The mechanism study showed that BT1500M changed Ampk and Nf-κb gene expression, and interrupted a crosstalk process between adipocytes and macrophages. Further investigation proved that BT1500M decreased endothelial lesion and subsequent macrophage activation, cytokines release, as well as cholesteryl ester gathering in the aortic arch, resulting in ameliorated artery plaque build-up. Our results provide a practical strategy for treating AS using a BBR-entrapped nano-system.
机译:动脉粥样硬化(AS)是心脏病发作,中风和外周血血管疾病的主要原因。 Berberine(BBR)是一种植物医学,具有多样化的抗动脉粥样硬化作用,但吸收不良。本研究的目的是开发一种用于以高脂饮食(HFD)的饮食( - / - )小鼠为处理的有效BBR簇纳米系统,并且还探讨了所涉及的可能的潜在机制。合成具有不同PEG链长度的三种D-α-生育酚聚乙二醇(PEG)琥珀酸盐(TPGS)类似物以配制BBR捕集的胶束。将HFD喂养的apoE( - / - )小鼠用优化的式(BBR,100mg / kg /天)口服5个月施用。评估动脉斑块发作和相关的代谢障碍,研究了潜在机制。我们的数据显示,BT1500M在肝脏中增加BBR沉积,分别脂肪沉积107.6%和172.3%。在Apoe(/ - )小鼠中,BT1500M改善了HFD诱导的肝脏和脂肪脂质积累的高脂质血症和脂质积累。 BT1500M还抑制了HFD诱导的慢性炎症,如中白蛋白-6(IL-6),肿瘤坏死因子-α(TNF-α)和白细胞介素-1β(IL-1β)的降低和脂肪水平证明。 TNF-α,IL-6,IL-1β,干扰素-γ(IFN-γ),单核细胞趋化蛋白(MCP)和巨噬细胞炎症因子(MIP)的血浆水平降低。该机制研究表明,BT1500M改变了AMPK和NF-κB基因表达,并中断了脂肪细胞和巨噬细胞之间的串扰过程。进一步调查证明,BT1500M降低内皮病变和随后的巨噬细胞活化,细胞因子释放,以及在主动脉弓中聚集的胆囊酯,导致改善动脉斑块积聚。我们的结果提供了使用BBR陷阱纳米系统治疗的实际策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号